← Back to Search

Virus Therapy

Vaccinated with polio vaccine (IPV) for COVID-19

Phase 4
Waitlist Available
Research Sponsored by E-MO Biology Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 28
Awards & highlights

Study Summary

Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19)

Eligible Conditions
  • COVID-19

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 28
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 28 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Subjects with Antibodies to SARS-CoV-2 RdRp following IPV Vaccination
Secondary outcome measures
Determination of neutralizing titer of antibodies raised to SARS-CoV-2 following vaccination with polio vaccine

Trial Design

1Treatment groups
Experimental Treatment
Group I: Vaccinated with polio vaccine (IPV)Experimental Treatment1 Intervention
All subjects will receive polio vaccine: IPV as manufactured by Sanofi Pasteur for distribution in the United States

Find a Location

Who is running the clinical trial?

E-MO Biology IncLead Sponsor
John AndrewsStudy ChairE-MO Biology Inc

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~68 spots leftby Apr 2025